Condition
Metastatic Cancer Clinical Trials
Studies of metastatic cancer, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 2,002Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the…
- Conditions
- Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma
- Trial name
- NCT01174121
- Testing
- Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the…
- Conditions
- Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
- Trial name
- NCT05058651
- Testing
- Atezolizumab, Biospecimen Collection, Carboplatin
- Where
- 265 sites in United States
- Volunteers
- 189 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT05136196
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate
- Where
- 231 sites in United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in…
- Conditions
- Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
- Trial name
- SAMURAI (NCT05327686)
- Testing
- Avelumab, Axitinib, Biospecimen Collection
- Where
- 348 sites in United States, Australia and 2 more
- Volunteers
- 240 people
- Sponsor
- NRG Oncology
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-positive salivary gland cancer that has come back (recurrent), that has spread…
- Conditions
- Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8
- Trial name
- NCT05408845
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 154 sites in United States
- Volunteers
- 146 people
- Sponsor
- NRG Oncology
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have…
- Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT06203600
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 377 sites in United States
- Volunteers
- 224 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated…
- Conditions
- Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Trial name
- NCT06422806
- Testing
- Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin
- Where
- 268 sites in United States, Canada and 1 more
- Volunteers
- 365 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement…
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT06589804
- Testing
- Biospecimen Collection, Cetuximab, Computed Tomography
- Where
- 201 sites in United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated.
- Trial name
- NCT06634875
- Testing
- isunakinra
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Buzzard Pharmaceuticals
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or…
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
- Trial name
- NCT06922591
- Testing
- TNG462, RMC-9805, RMC-6236
- Where
- 18 sites in United States
- Volunteers
- 183 people
- Sponsor
- Tango Therapeutics, Inc.